GENITOURINARY CANCERS

For Prostate Cancer Awareness Month, Jeffrey Y.C. Wong, MD, discussed the evolving field of prostate cancer treatment and how it continues to improve.

Arnab Basu, MD, MPH, FACP, discussed his research on high-sensitivity circulating tumor DNA assays in genitourinary malignancies.

Arnab Basu, MD, MPH, FACP, discusses his research on high sensitivity circulating tumor DNA assays in genitourinary malignancies.

Anil Parwani, MD, PhD, discusses the challenges and opportunities he has encountered in either implementing or utilizing artificial intelligence technology in the clinical setting.

Jacob E. Berchuck, MD, discusses research behind using a blood-based liquid biopsy over traditional PSMA PET scans presented at the 2024 ESMO Congress.

Matthew Galsky, MD, discusses why some physicians were surprised at the positive outcomes of nivolumab trials in bladder cancer compared with trials of similar agents.

The ARANOTE trial confirmed radiographical PFS benefit to adding darolutamide to androgen deprivation therapy without docetaxel in the metastatic hormone-sensitive prostate cancer setting.

The RAPSON trial found that receiving radium-223 prior to docetaxel in patients with metastatic castration-resistant prostate cancer improved quality of life and tolerability compared to the reverse sequence, without affecting progression-free survival or overall survival.

Adding radium-223 to enzalutamide significantly improved survival outcomes in patients with metastatic castration-resistant prostate cancer and bone metastases.

Anil Parwani, MD, PhD, addresses potential biases or limitations in the artificial intelligence algorithm used at his institution.

The FDA has approved FoundationOne CDx and FoundationOne Liquid CDx as companion diagnostics to be used with olaparib, abiraterone, and prednisone or prednisolone BRCA-mutated metastatic castration-resistant prostate cancer.

Anil Parwani, MD, PhD, discusses the use of artificial intelligence technology to enhance cancer diagnostics and treatment.

Anil Parwani, MD, PhD, discusses how the use of artificial intelligence technology can be integrated into the current workflow of pathologists.

Anil Parwani, MD, PhD, professor of pathology at The Ohio State University Wexner Medical Center, discusses the artificial intelligence (AI) technology that is currently being used at his institution.

64Cu-SAR-bisPSMA gained FDA fast track status for advanced prostate cancer imaging.

The US label for lenvatinib has been updated to include new clinical efficacy data for its use as a first-line treatment in advanced non-clear cell renal cell carcinoma, based on results from the KEYNOTE-B61 trial.

Matthew Galsky, MD, discusses the disease-free survival of nivolumab vs placebo in patients with high-risk muscle-invasive bladder cancer.

Neeraj Agarwal, MD, discusses some of the unmet needs that exist in the prostate cancer space.

In an interview, Benjamin H. Lowentritt, MD, FACS, compared PSA response rates between apalutamide and enzalutamide in patients with metastatic castration-sensitive prostate cancer.

Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.

Findings from the phase 3 ARANOTE trial demonstrated an improvement in radiographic progression-free survival with darolutamide vs placebo plus androgen deprivation therapy in metastatic hormone-sensitive prostate cancer.

Scott T. Tagawa, MD, MS, FACP, FASCO, discusses the potential benefits of antibody-drug conjugates in urothelial cancer while acknowledging the need for more education and experience among physicians to optimize their use.

BNT324/DB-1311 gained fast track designation from the FDA in unresectable advanced or metastatic castration-resistant prostate cancer who have progressed after standard treatments.

The FDA has granted fast track designation to 225Ac-FL-020, a promising PSMA-targeting radionuclide drug conjugate for metastatic castration-resistant prostate cancer.

Adam Weiner, MD, discusses his journey toward becoming an oncologist with a focus in urology in this episode of Emerging Experts.